Stocktoria

HARTE HANKS INC HHS

Nasdaq · stock · Services-Direct Mail Advertising Services · website · IPO 1993-11-04 · LEI

HARTE HANKS INC (HHS) earns a Piotroski F-score of 2/9 (weak financial health). It pays a dividend yielding 34.41% (safety: no dividend). FY2025 revenue was $159.6M at a -0.5% net margin.

Chart by TradingView
13/100
Stocktoria Quality Score · grade D
2/9
Piotroski F — financial health
Altman Z″ — distress risk
3.4%
Dividend yield 5y avg · no dividend

Quality score trend · recomputed for each fiscal year

Piotroski F /9
4 3 3 2 2 4 4 3 3 2 2016201720182019202020212022202320242025
Altman Z″
12.48 19.29 2016201720182019202020212022202320242025

Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.

$2.51 as of 2026-08-01 · -30.3% 1y
$2.16$3.7752-wk
Market cap USD$15M
Dividend yield 5y avg3.4%
Net margin 5y avg1.6%
Beta-0.04
Employees1,719
Revenue trend · last 10y · down

How it ranks in Services · percentile among 982 companies

Piotroski Fstronger than 7%
Net marginstronger than 51%
Return on equitystronger than 42%
Revenue growthstronger than 9%

Percentile vs other Services companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.

Piotroski F breakdown · 2/9 tests passed

Sector peers · similar-size Services companies compare side by side →

TickerCompanyPiotroski FAltman Z″P / ERevenue growth
HHSHARTE HANKS INC2/9-13.9%
GOOGAlphabet Inc.5/96.7931.1+15.1%
MSFTMICROSOFT CORP6/94.4920.7+17.8%
METAMeta Platforms, Inc.4/95.3423.1+22.2%
BABAAlibaba Group Holding Ltd3/9+8.1%
DISWalt Disney Co7/92.7213.8+3.4%
HCAHCA Healthcare, Inc.6/912.8+7.1%

All Services companies →

About HARTE HANKS INC

Harte Hanks, Inc. operates as a customer experience company in the United States and internationally. It operates through three segments: Revenue Solutions, Customer Care, and Fulfillment and Logistics. It offers data and analytics, including audience identification, profiling, segmentation and prioritization, and predictive modeling and data strategy; research and intelligence, helps in understanding of customers, category, competitors, and capabilities; strategy, which plans and executes omnichannel marketing, demand generation, and customer experience programs; creative and content, including creative concepts, messaging and content assets for print, broadcast, direct mail, website, app, display, social, mobile, search engine marketing, and voice; marketing technology, a website and app development, e-commerce development and enablement, database building and management, platform architecture creation, and marketing automation; digital and multi-channel marketing execution and advertising; demand generation and account based marketing; and managed marketing services. It also provides product, print-on-demand, and mail fulfillment services, including as printing on demand and distributing literature, managing product recalls, and promotional and branded product distribution; and third-party logistics and freight optimization services. In addition, the company offers inside sales outsourcing, which provides B2B enterprises, and small to midsized businesses with an outsourced sales service; lead generation services; and sales play development, as well as customer service outsourcing, customer care technology and artificial intelligence transformation, and self-service technology. It serves B2B, healthcare, pharmaceuticals, health insurance, consumer, travel, hospitality, streaming, entertainment, quick service restaurants, financial, fintech, automotive, and retail industries. The company was founded in 1923 and is headquartered in Chelmsford, Massachusetts.

FAQ

Is HHS financially healthy?

HARTE HANKS INC's Piotroski F-score is 2/9 (8–9 is excellent, 0–3 weak).

Does HHS pay a dividend, and is it safe?

Yes. HARTE HANKS INC pays a dividend yielding about 34.41% with a None payout ratio, rated “no dividend” for safety.

How profitable is HHS?

In FY2025, HARTE HANKS INC had a net margin of -0.5% and a return on equity of -4.0%.

Is HHS overvalued or undervalued?

HARTE HANKS INC trades at about 0.5× trailing earnings — below its 10-year norm (10-year range 1.3×–326.2×, median 137.9×). Stocktoria reports the data, not buy/sell advice.

Is HHS a good stock to buy?

Stocktoria doesn't give buy or sell advice, but here is the data on HARTE HANKS INC: a Piotroski F-score of 2/9, a dividend yield of 34.41%. Weigh these quality and valuation signals against your own goals.

Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.